Magnetoliposomes in controlled-release drug delivery systems

被引：13
作者：
Tomitaka A. [1 ]
Takemura Y. [2 ]
Huang Z. [3 ]
Roy U. [4 ]
Nair M. [1 ]
机构：
[1] Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Centre for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL
[2] Department of Electrical and Computer Engineering, Yokohama National University, Yokohama
[3] Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL
[4] Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX
来源：
Critical Reviews in Biomedical Engineering | 2019年 / 47卷 / 06期
基金：
美国国家卫生研究院;
关键词：
Drug delivery; Liposomes; Magnetic nanoparticles; Magnetoliposomes;
D O I：
10.1615/CritRevBiomedEng.2020033002
中图分类号：
学科分类号：
摘要：
Liposomes, one of the most promising drug delivery carriers, have been extensively studied for the treatment of various diseases and have made their way to the market. Magnetic nanoparticles have been attracting great interest for diagnostic and therapeutic applications due to their unique magnetic properties. An integration of liposomes and magnetic nanoparticles gives great potential to the field of smart drug delivery systems, including magnetically guided drug delivery, image-guided drug delivery, and externally triggered controlled drug release using hyperthermia or alternating magnetic fields. In this review, we discuss the recent development of magnetoliposomes for controlled-release drug delivery systems and their potential. © 2019 by Begell House, Inc. www.begellhouse.com.
引用
收藏
页码：495 / 505
页数：10
相关论文
共 67 条
  • [11] Jayant R.D., Atluri V.S.R., Agudelo M., Sagar V., Kaushik A., Nair M., Sustained-release nanoART formulation for the treatment of neuroAIDS, Int J Nanomedicine, 10, pp. 1077-1093, (2015)
  • [12] Allen T.M., Cullis P.R., Liposomal drug delivery systems: From concept to clinical applications, Adv Drug Deliv Rev, 65, 1, pp. 36-48, (2013)
  • [13] Malam Y., Loizidou M., Seifalian A.M., Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer, Trends Pharmacol Sci, 30, 11, pp. 592-599, (2009)
  • [14] Laouini A., Jaafar-Maalej C., Limayem-Blouza I., Sfar S., Charcosset C., Fessi H., Preparation, characterization and applications of liposomes: State of the art, J Colloid Sci Biotechnol, 1, 2, pp. 147-168, (2012)
  • [15] Barenholz Y.C., Doxil ®—The first FDA-approved na-no-drug: Lessons learned, J Control Release, 160, 2, pp. 117-134, (2012)
  • [16] Gluer C.C., Medina T.P., Medina O.P., Magnetoliposomes: Formation and structural characterization, Liposomal Deliv Syst Adv Challenges., 1, pp. 62-73, (2015)
  • [17] Garnier B., Tan S., Miraux S., Bled E., Brisson A.R., Opti-mized synthesis of 100 nm diameter magnetoliposomes with high content of maghemite particles and high MRI effect, Contrast Media Mol Imaging, 7, 2, pp. 231-239, (2012)
  • [18] Garcia Ribeiro R.S., Gysemans C., da Cunha J.P.M.C.M., Manshian B.B., Jirak D., Kriz J., Gallo J., Banobre-Lopez M., Struys T., de Cuyper M., Mathieu C., Soenen S.J., Gsell W., Himmelreich U., Magnetoliposomes as contrast agents for longitudinal in vivo assessment of transplanted pancreatic islets in a diabetic rat model, Sci Rep, 8, (2018)
  • [19] Ito A., Fujioka M., Yoshida T., Wakamatsu K., Ito S., Ya-Mashita T., Jimbow K., Honda H., 4-S-cysteaminylphe-nol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against ma-lignant melanoma, Cancer Sci, 98, 3, pp. 424-430, (2007)
  • [20] Jabalera Y., Fernandez-Vivas A., Iglesias G.R., Delgado A.V., Jimenez-Lopez C., Magnetoliposomes of mixed biomi-metic and inorganic magnetic nanoparticles as enhanced hyperthermia agents, Colloids Surfaces B Biointerfaces [Internet]., 183, (2019)
1234567